----- SPECIAL EDITION -----
European Association for the Study of Diabetes (EASD) 2025
PICTURE CREDIT: EASD – European Association for the Study of Diabetes
The 61st Annual Meeting of the European Association for the Study of Diabetes (EASD) was held this week in Vienna, Austria, bringing together thousands of healthcare professionals both in person and online.
The conference programme featured a wide range of daily sessions, including plenary lectures, symposia and workshops.
Speakers from across the globe presented the latest advances in diabetes treatment and explored some of the most pressing and debated issues in disease management.
New research presented at the Annual Meeting of the European Association for the Study of Diabetes 2025 shows that daily treatment with the new once-daily GLP-1 agonist orforglipron results in substantial weight loss in people living with obesity that do not have type 2 diabetes.
The study is by Dr Sean Wharton, McMaster University, Hamilton, ON, Canada and Wharton Weight Management Clinic, Burlington, ON, Canada, and colleagues. The study is sponsored by Eli Lilly, the manufacturer of orforglipron.
The European Association for the Study of Diabetes (EASD) is urging health systems to introduce population-wide screening for type 1 diabetes in young children, starting between the ages of two and four.
Most children who go on to develop the condition do not have a close family history of the disease.
An international type 2 diabetes expert presented the latest findings from the REDEFINE 2 study at the prestigious European Association for the Study of Diabetes (EASD) 2025 meeting.
Professor Melanie Davies, from the University of Leicester, gave delegates a first look at the results, showing that once-weekly CagriSema 2.4 mg/2.4 mg provided clinically meaningful weight reduction in adults with overweight or obesity and type 2 diabetes.
Tirzepatide can cause clinically meaningful improvements in blood sugar control and weight loss in adolescents with type 2 diabetes whose condition is inadequately controlled with an existing treatment regimen of metformin, insulin, or both.
The study (the SURPASS-PEDS trial), by Dr Tamara Hannon, Division of Pediatric Endocrinology and Diabetology, Indiana University School of Medicine, Indiana University School of Medicine, Indianapolis, USA, and colleagues was presented at this year’s Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria (15-19 September) and published in The Lancet.
In adults with type 1 diabetes and obesity, low dose tirzepatide reduced their weight, HbA1c levels and insulin dose requirements, a clinical trial has demonstrated. To read more, click here.
New research presented at this year’s EASD shows that tirzepatide, used to treat type 2 diabetes and/or obesity, can also be used as a co-therapy for type 1 diabetes. To read more, click here.
Glycaemic control improved immediately after using the MiniMed 780G system and remained stable over three years, a new study has shown. To read more, click here.
Roche announced its integration with the mySugr diabetes management app at the European Association for the Study of Diabetes 2025. To read more, click here.
GLP-1 receptor agonist drugs protect against diabetic retinopathy – a common complication of diabetes that can lead to sight loss.
This research was presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria (15-19 September) and published in the journal Pharmaceutics.
The European Association for the Study of Diabetes (EASD) has finalised the draft of its first evidence-based clinical practice guideline.
It focuses on the assessment and management of diabetes distress among adults with type 1 diabetes and type 2 diabetes and is the world’s first to focus on diabetes distress.
Vertex Pharmaceuticals shared more data from the Phase 1/2 FORWARD clinical trial, investigating the use of zimislecel for treating type 1 diabetes complicated by severe hypoglycaemic events. To read more, click here.
A simple breath test could soon be a cheaper and quicker way to diagnose diabetes and pre-diabetes, thanks to a new device, according to a recent research investigation. To read more, click here.
New research shows that people with hepatitis B immunity induced by vaccination have a lower risk of developing diabetes of any kind. To read more, click here.
A new study presented at EASD 2025 found that half of adults without diabetes who started taking semaglutide in Denmark discontinued treatment within a year. To read more, click here.
Living with type 2 diabetes may double the risk of developing sepsis, especially for those aged younger than 60 years and men, according to a long-term community-based study in Australia. To read more, click here.
A company driving breakthroughs in non-invasive continuous glucose monitoring has been shortlisted for Company of the Year (Under 50 employees) at the Wales STEM Awards 2025. To read more, click here.
New research presented at this year’s Annual Meeting of The European Association for the Study of Diabetes (EASD), Vienna (15-19 Sept), revealed type 2 diabetes is a critical factor in chronic disease accumulation, particularly during the early stages.
Lead author Dr Jie Zhang said: “Concerningly, people with type 2 diabetes showed faster progression to diseased states compared to those without the condition."
The first study of its kind shows that younger men with type 2 diabetes have worse mortality and cardiovascular disease (CVD) outcomes than those with type 1 diabetes. To read more, click here.
People with both type 2 diabetes and obstructive sleep apnoea have a higher risk of death, but treatment with continuous positive airway pressure (CPAP) may reduce that risk by around 26 per cent. To read more, click here.
A new review finds that experiencing gestational diabetes during pregnancy is linked with a decline in intellectual function among mothers, and may increase autism spectrum disorder and attention-deficit/hyperactivity disorder in children. To read more, click here.
Professor Gerry Rayman, GIRFT joint clinical lead for diabetes, will host a webinar on Tuesday 24 September at 1pm to explore the benefits of the newly launched Community and District Nurse Insulin Programme (CADNIP). To read more, click here.
People from Afro-Caribbean and South Asian backgrounds are less likely to be prescribed “life-changing” diabetes technology compared to White individuals, a new study has reported.
Researchers at the University of Leicester have drawn attention to stark health inequalities in access to continuous glucose monitors (CGMs), despite these ethnic groups facing a higher risk of developing diabetes, and often at a younger age.
New research presented at the European Association for the Study of Diabetes showed that smoking increases the risk of type 2 diabetes, regardless of subtype. To read more, click here.
Cannabis use is linked to an almost quadrupling in the risk of developing diabetes, according to an analysis of real-world data from over four million adults. To read more, click here.
An increased cardiovascular risk was found for oral HRT, according to a large real-world study presented at this year’s Annual Meeting of The European Association for the Study of Diabetes (EASD). To read more, click here.
The relative increase in odds of an individual with diabetes developing severe symptoms of depression – and vice versa – is the same, regardless of where they live. To read more, click here.
Educating care home staff about the management of diabetes is an essential part of ensuring safe, high-quality care for residents.
Over the past four years, the Leicester Diabetes Centre’s Eden team, working in collaboration with Sanofi, has successfully delivered Sanofi CARES – an award-winning online education programme for care home staff.
Hypo Awareness Week 2025 has been funded by Sanofi and embecta, who have had no input into any arrangements or content.
There is still time to register for Hypo Awareness Week 2025 which will be held from Monday, 6 October to Sunday, 12 October. To read more, click here.
A point-of-care diagnostics solutions provider has donated more than £40,000 worth of diabetes supplies to help people living with the condition in Sierra Leone. To read more, click here.
Bringing you the latest jobs from around the country within the field of diabetes.
Specialist Diabetes Midwife – Tameside and Glossop Integrated Care NHS Foundation Trust
Diabetes Specialist Dietitian – Bromley Healthcare CIC
Consultant in Diabetes, Endocrinology and General Medicine – The Shrewsbury and Telford Hospital NHS Trust
Diabetes Specialist Dietitian – Sussex Community NHS Foundation Trust
